Sutro Biopharma, Inc. (STRO)
After hours:
| Previous close | 4.0100 |
| Open | 4.0100 |
| Bid | 3.9000 x 100 |
| Ask | 3.9600 x 200 |
| Day's range | 3.9000 - 4.2100 |
| 52-week range | 2.0100 - 6.1300 |
| Volume | |
| Avg. volume | 766,107 |
| Market cap | 323.757M |
| Beta (5Y monthly) | 1.18 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.7800 |
| Earnings date | 11 Nov 2024 - 15 Nov 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 12.00 |
GlobeNewswireSutro Biopharma Announces Updated Data from Phase 1b Study of Luvelta in Combination with Bevacizumab at ESMO 2024
- 4.3 mg/kg of luveltamab tazevibulin (luvelta) in combination with standard dose of bevacizumab (15 mg/kg) every 3 weeks resulted in a 56% objective response rate in patients with late-stage ovarian cancer and was selected to be the recommended phase 2 dose (RP2D) - - Luvelta in combination with bevacizumab demonstrated encouraging preliminary antitumor activity (35% response rate) across all explored dose ranges - - Expansion at RP2D is ongoing with an additional 23 patients enrolled to date;
- GlobeNewswire
Sutro Biopharma to Host Research Forum Highlighting Next-Generation ADC Innovation and Near-term Pipeline, on October 10, 2024
SOUTH SAN FRANCISCO, Calif., Sept. 11, 2024 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that it will host a Research Forum to highlight its pipeline of next-generation ADCs. The live webcast will be held on Thursday, October 10, 2024, starting at 1:30 p.m. PT / 4:30 p.m. ET. Webcast Information:To access the live audio webcast on Thursd
ZacksSutro Biopharma (STRO) Rises 9% in the Past Week: Here's Why
Sutro Biopharma (STRO) gains 9% in a week after initiating a phase II study on its lead candidate, luvelta, to treat FRa-expressing lung cancer.
